Treatment of Fanconi Anemia with Early-Stage Myelodysplastic Syndrome (Without Excess Blasts)
When Fanconi anemia is complicated by early-stage myelodysplastic syndrome (MDS) without excess blasts, the clinical picture calls for a specific, well-defined management strategy — distinct from watch-and-wait approaches used in other settings.
Clinical scenario: Fanconi anemia with early-stage myelodysplastic syndrome without excess blasts. For this presentation, most centers recommend a direct interventional approach rather than continued observation.
Approach overview: The recommended strategy centres on hematopoietic stem cell transplantation with the best available donor, incorporating specific T-cell depletion strategies — the complete protocol, including donor selection criteria, conditioning approach, and post-transplant management, is available via the link below.
References
DOI: 10.1182/hematology.2023000489
- For patients with early-stage MDS without excess blasts such as the one in our case, most centers recommend proceeding directly to HSCT with best available donor.
- Subsequently, improved outcomes have been made possible by T-cell depletion strategies such as CD34 selection and TCRαβ depletion to limit graft-versus host disease (GvHD) and by use of low-intensity regimens to reduce organ toxicity.
- Posttransplant cyclophosphamide has also proven to be an effective method of in vivo T-cell depletion for patients with FA undergoing HSCT with haploidentical donors.
View source ↗